HCPLive Network

Preventive Measures Not Enough to Combat Clostridium Difficile Infection

THURSDAY, March 14 (HealthDay News) -- Although measures have been adopted to combat Clostridium difficile infection (CDI), most facilities have not reported improvement in health care facility-associated CDI rates, according to survey findings published by the Association for Professionals in Infection Control and Epidemiology (APIC).

To get an overview of trends at APIC member facilities, 1,087 U.S. APIC members were surveyed from Jan. 14 to 28, 2013, regarding policies and practices put in place to address CDI since March 2010.

The researchers found that only 21 percent of respondents reported having been able to add more infection prevention staff in the previous three years, although CDI rates are at historic highs. Seventy-eight percent of respondents reported using the APIC Implementation Guide on CDI to help identify or lead improvements. Although 70 percent of respondents reported having adopted additional interventions to address CDI since March 2010, less than half (42 percent) reported a decline in the rate of health care facility-associated CDI rates. Of the respondents who had not adopted more aggressive measures to combat CDI, most reported that the best practices were already in place (65 percent) or that CDI was not a high-priority problem for their facility (37 percent). Most respondents (85 percent) had participated in education offerings about CDI, but only 50 percent had initiated patient education programs.

"We are encouraged that many institutions have adopted stronger measures to prevent CDI, but as our survey indicates, more needs to be done to reduce the spread of this infection," Jennie Mayfield, M.P.H., APIC-president elect, said in a statement.

More Information

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
A prognostic model has been developed and validated which has adequate discrimination for major outcomes in type 1 diabetes, according to a study published online Aug. 28 in Diabetologia.
The costs of Medicare associated with Sovaldi (sofosbuvir), an emerging hepatitis C drug, will vary depending on how many people are given the treatment, a blog in Health Affairs found.
For patients with cancer, factors associated with late admission to hospice have been identified, according to a study published online Aug. 25 in the Journal of Clinical Oncology.
Revised guidelines recommend athletes to drink when they are thirsty and to supplement post-training fluids with “recovery foods.”
Gastroparesis, or delayed gastric emptying, remains misunderstood despite rising prevalence, according to a news release from the International Foundation for Functional Gastrointestinal Disorders (IFFGD), a nonprofit research and education organization addressing issues surrounding gastrointestinal and motility disorders.
The European Commission (EU) has granted Bristol-Myers Squibb’s Daklinza (daclatasvir) approval for an all-oral drug regimen for the treatment of four genotypes of chronic hepatitis C infection.
A new multi-step skin testing protocol effectively determines the presence of isosulfan blue allergy, according to a study conducted by researchers at the University of Virginia.
More Reading